ViaDerma, a pharmaceutical company, announced entering a $250,000 initial sales agreement with Vage Nigeria Ltd, a brand support company that specialises in product sourcing.
According to the terms of the agreement, Vage will pay a 50 percent deposit to ViaDerma upon completion of the registration of Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA.
The registration process should be completed within 30 days. The balance of the order will be paid to ViaDerma upon delivery of the product in about 8-10 weeks.
- CBN suspends FX sales to BDCs, weekly FX allocations now for commercial banks
- Speculation, devaluation seen for naira in CBN’s stoppage of dollar…
- Nigeria's Security Funding
- Nigeria’s $2.8bn AKK gas pipeline on course for delivery, NNPC assures
- IMF keeps Nigeria’s GDP growth forecast at 2.5% in 2021, 2.6% in 2022
Christopher Otiko, President of ViaDerma, stated “We are very pleased to be working together with Vage and Kunle Craig, their CEO, to provide Vitastem to the people of Nigeria. This is only the first of many orders we expect to receive from Vage going forward.”
Kunle Craig, CEO of Vage Nigeria Ltd. said “Vitastem is a wonderful ointment that has exceeded all expectations during our testing. The feedback received and the results we have seen have so far been 100% positive. Infections have cleared up in just 3 days, and leg burns have seen significant improvement within 24 hours of application.
“I have witnessed firsthand the positive results brought upon by Vitastem in wound and skin treatment, and I have become a firm believer in this product. From what I have observed, Vitastem is a revolutionary medication,” Craig said.
Nigeria November 21, 2019